# A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

> **NCT01718145** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 258 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Daclatasvir
- **DRUG:** Asunaprevir
- **DRUG:** Ribavirin
- **BIOLOGICAL:** pegIFNα-2b
- **DRUG:** Telaprevir

## Key facts

- **NCT ID:** NCT01718145
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-12
- **Final completion:** 2014-12
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01718145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01718145, "A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01718145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*